Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Jeng

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Zhonghua Yi Xue Za Zhi = Chinese Medical Journal; Free China Ed|May 1, 1993
DNA analysis and persistent hypercalcitoninemia in medullary thyroid carcinomaT K Jeng, C H Lee, H C Wang, et al.
Oncotarget|February 25, 2016
IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomasPeter S Kim, Anna R Kwilas, Wenxin Xu, et al.
Journal of Virology|April 3, 2015
In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized MiceKieran Seay, Candice Church, Jian Hua Zheng, et al.
Oncotarget|June 3, 2017
New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activityCavan P Bailey, Tulin Budak-Alpdogan, Christopher T Sauter, et al.
International Journal of Cancer|July 16, 2015
Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma modelDimitrios Mathios, Chul-Kee Park, Warren D Marcus, et al.
Cytokine|February 18, 2018
Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine modelsBai Liu, Monica Jones, Lin Kong, et al.
Nature Biotechnology|July 10, 2018
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug deliveryLi Tang, Yiran Zheng, Mariane Bandeira Melo, et al.
Cancer Research|May 7, 2013
Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myelomaWenxin Xu, Monica Jones, Bai Liu, et al.
The Journal of Biological Chemistry|September 22, 2016
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor ResponsesBai Liu, Lin Kong, Kaiping Han, et al.
Cancer Research|April 12, 2018
Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8<sup>+</sup> T CellsC Bryce Johnson, Bennett R May, Brian P Riesenberg, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Zhonghua Yi Xue Za Zhi = Chinese Medical Journal; Free China Ed|May 1, 1993
DNA analysis and persistent hypercalcitoninemia in medullary thyroid carcinomaT K Jeng, C H Lee, H C Wang, et al.
Oncotarget|February 25, 2016
IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomasPeter S Kim, Anna R Kwilas, Wenxin Xu, et al.
Journal of Virology|April 3, 2015
In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized MiceKieran Seay, Candice Church, Jian Hua Zheng, et al.
Oncotarget|June 3, 2017
New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activityCavan P Bailey, Tulin Budak-Alpdogan, Christopher T Sauter, et al.
International Journal of Cancer|July 16, 2015
Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma modelDimitrios Mathios, Chul-Kee Park, Warren D Marcus, et al.
Cytokine|February 18, 2018
Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine modelsBai Liu, Monica Jones, Lin Kong, et al.
Nature Biotechnology|July 10, 2018
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug deliveryLi Tang, Yiran Zheng, Mariane Bandeira Melo, et al.
Cancer Research|May 7, 2013
Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myelomaWenxin Xu, Monica Jones, Bai Liu, et al.
The Journal of Biological Chemistry|September 22, 2016
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor ResponsesBai Liu, Lin Kong, Kaiping Han, et al.
Cancer Research|April 12, 2018
Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8<sup>+</sup> T CellsC Bryce Johnson, Bennett R May, Brian P Riesenberg, et al.
Pageof 4